Abstract:The emergence of chimeric antigen receptor T cell (CAR-T cell) therapy has revolutionized cancer treatment, particularly for hematologic malignancies. This commentary discusses developments in CAR-T cell therapy, focusing on the molecular mechanisms governing T cell fate and differentiation. Transcriptional and epigenetic factors play a pivotal role in determining the specificity, effectiveness, and durability of CAR-T cell therapy. Understanding these mechanisms is crucial to improve the efficacy and decrease the adverse events associated with CAR-T cell therapies, unlocking the full potential of these approaches. T cell differentiation in CAR-T cell product manufacturing plays an important role in clinical outcomes. A positive correlation exists between the clinical efficacy of CAR-T cell therapy and signatures of memory, whereas a negative correlation has been observed with signatures of effector function or exhaustion. The effectiveness of CAR-T cell products is likely influenced by T-cell frequency and by their ability to proliferate, which is closely linked to early T cell differentiation. The differentiation process involving distinct T memory cell subsets is initiated upon antigen elimination, indicating infection resolution. In chronic infections or cancer, T cells may undergo exhaustion, marked by continuous inhibitory receptor expression, decreased cytokine production, and diminished proliferative capacity. Other cell subsets, such as CD4+ T cells, innate-like T lymphocytes, NKT cells, and cord blood-derived hematopoietic stem cells, offer unique advantages in developing the next-generation CAR-T cell-based therapies. Future research should focus on optimizing T-cell-enhancing approaches and developing strategies to potentially cure patients with hematological diseases and solid tumors.

Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

Enhancing the Efficacy of CAR-T Cell Therapy: A Comprehensive Exploration of Cellular Strategies and Molecular Dynamics

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

CAR T-cell Immunotherapy: a Powerful Weapon for Fighting Hematological B-cell Malignancies

Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy

Challenges and optimal strategies of CAR T therapy for hematological malignancies.

Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion

Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy

Unlocking T cell exhaustion: Insights and implications for CAR-T cell therapy

Engineering Chimeric Antigen Receptor-T Cells for Cancer Treatment

Metabolic challenges and interventions in CAR T cell therapy

CAR-T Cells Shoot for New Targets: Novel Approaches to Boost Adoptive Cell Therapy for B Cell-Derived Malignancies

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Current progress in CAR-T cell therapy for tumor treatment

CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges

Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy

Current Clinical Application of the CAR-T Cell Therapy

CAR-T cell combination therapies in hematologic malignancies